Dr. Trent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1475 NW 12th Ave
Fl 1
Miami, FL 33136Phone+1 305-243-2581Fax+1 305-243-1293- Is this information wrong?
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1995 - 1998
McGovern Medical School at UTHealthClass of 1995
Certifications & Licensure
FL State Medical License 2011 - 2026
TX State Medical License 1997 - 2013- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
- The National Board of Physicians and SurgeonsMedical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery Start of enrollment: 2005 Sep 01
- Ph II Study of Perifosine Plus Gleevec for Patients With GIST Start of enrollment: 2006 Aug 01
- Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST Start of enrollment: 2003 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsRipretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.Michael C Heinrich, Robin L Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John R Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonat...> ;Nature Medicine. 2024 Feb 1
- 2 citationsRethinking placebos: embracing synthetic control arms in clinical trials for rare tumors.César Serrano, Sara Rothschild, Guillermo Villacampa, Michael C Heinrich, Suzanne George, Jean-Yves Blay, Jason K Sicklick, Sameer Rastogi, Robin L Jones, Piotr Rutkow...> ;Nature Medicine. 2023 Nov 1
- Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) Is a Novel Therapeutic Target in Liposarcoma: A Tissue Microarray Study.Dylan C Dean, Wenlong Feng, Robert L Walker, Pichaya Thanindratarn, H Thomas Temple, Jonathan C Trent, Andrew E Rosenberg, Francis J Hornicek, Zhenfeng Duan> ;Clinical Orthopaedics and Related Research. 2023 Nov 1
- Join now to see all
Press Mentions
Sylvester Recruits Aman Chauhan, M.D., to Lead Neuroendocrine Tumor ProgramMarch 16th, 2023- Sylvester Stands Out at ASCO’s 2022 Annual Meeting in ChicagoJune 21st, 2022
- Precision Medicine Advances in Cancer Treatment Highlighted at Inaugural Sylvester ConferenceApril 12th, 2022
- Join now to see all
Grant Support
- Chaperonin (Sulfolobus Shibatae)National Center For Research Resources2006–2009
- Activity &Resistance Of Gleevec In GI Stromal TumorsNational Cancer Institute2004–2008
- Mechanism/Activity/Resistance/Gleevec/Gi Stromal Tumors (K23M)National Cancer Institute2005–2006
- Chaperonins As Self-Assembling Building Blocks For NanotechnologyNational Center For Research Resources2005
- Characterize Struct Of Molecular Chaperones Cytostructure Of Prokaryotic CellNational Center For Research Resources1998
- Chaperonin Filaments Archaeal CytostructureNational Center For Research Resources1998
Professional Memberships
- Member
Hospital Affiliations
University of Miami HospitalMiami, Florida
UMHC-Sylvester Comprehensive Cancer CenterMiami, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
